iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan ‐O‐ AP and LixiLan ‐L‐ CN studies
Authors' conclusion
In Asian people with T2D suboptimally controlled on OADs or BI, iGlarLixi provided comprehensive earlier glycaemic control than Gla-100.
Study context
- Population
- Asian people with suboptimally controlled T2D on oral antidiabetic drugs (OADs) (LixiLan-O-AP) or basal insulin ± OADs (LixiLan-L-CN)
- Comparison
- iGlarLixi vs insulin glargine 100 U/mL
- Primary endpoint
- Early glycaemic control: change from baseline in HbA1c, FPG and PPG
- Follow-up
- Week 12
Primary result
As reported in the abstract
Mean HbA1c reduction
LixiLan-O-AP: greater HbA1c reduction with iGlarLixi vs Gla-100
−1.6% vs. −1.1%
−17.0 vs. −12.0 mmol/mol
LixiLan-L-CN: greater HbA1c reduction with iGlarLixi vs Gla-100
−1.3% vs. −0.5%
−13.9 vs. −5.4 mmol/mol
Further findings
PPG and FPG reductions · Week 12
- PPG reductions greater with iGlarLixi; FPG reductions similar
Achievement of target HbA1c or PPG · Weeks 8 and 12
- More participants achieved target HbA1c or PPG with iGlarLixi vs Gla-100 in both studies
Median time to HbA1c and PPG targets
- LixiLan-O-AP, HbA1c target: shorter with iGlarLixi vs Gla-100
- 85 vs. 126 days
- LixiLan-O-AP, PPG target: shorter with iGlarLixi vs Gla-100
- 84 vs. 167 days
- LixiLan-L-CN, HbA1c target: shorter with iGlarLixi vs Gla-100
- 85 vs. 239 days
- LixiLan-L-CN, PPG target: shorter with iGlarLixi vs Gla-100
- 85 days vs. not estimable
Median time to FPG target
- LixiLan-O-AP: similar, iGlarLixi vs Gla-100
- 57 vs. 57 days
- LixiLan-L-CN: similar, iGlarLixi vs Gla-100
- 29 vs. 30 days
Safety
- Hypoglycaemia incidence similar with iGlarLixi and Gla-100
Original publication
iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan ‐O‐ AP and LixiLan ‐L‐ CN studies. Diabetes Obes Metab. Published 27 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →